Back to search
FDAFDA · Food and drugs·Recall number D-0577-2022

Bortezomib, 3.5 mg/vial, Single-Dose Vial, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Visakhapatnam - 530 046, India, NDC 43598-865-60

Published March 2, 2022 · Recall initiated: January 19, 2022

Summary

FDA records drug Class III recall D-0577-2022, published March 2, 2022 and initiated January 19, 2022. Recalling firm: Dr. Reddy's Laboratories, Inc.; Status: Terminated; Reported quantity: 2,980 vials; Lot: Lot # H210233, Exp 3/1/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed stability specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Dr. Reddy's Laboratories, Inc.
Distributor
USA Nationwide
Lot
Lot # H210233, Exp 3/1/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Bortezomib, 3.5 mg/vial, Single-Dose Vial, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Visakhapatnam - 530 046, India, NDC 43598-865-60 recalled?

Yes. FDA published recall D-0577-2022 on March 2, 2022. Reported hazard: Failed stability specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter